Advancing novel treatments for dry eye and ocular surgery


Kala (NASDAQ: KALA) is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both the front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Beyond ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health, respiratory and gastrointestinal diseases, and other indications.


Year Invested: 2009
Location: Waltham, Mass.
Visit: www.kalarx.com

Recent News

October 2, 2017
Kala Pharmaceuticals Appoints Andrew I. Koven To Board Of Directors

September 5, 2017
Kala Pharmaceuticals to Present At The 2017 Wells Fargo Healthcare Conference

July 25, 2017
Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters’ Option

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner